Ruti Aga Gets Six-Year Ban: A Family Member Forged the Prescription

The Athletics Integrity Unit (AIU) has banned Ethiopian marathon runner Ruti Aga for six years. The 32-year-old tested positive after winning a half marathon in China in March. But the centre of this case is not the drug found in her sample — it is the document she submitted in her defence: a forged prescription, allegedly prepared by a member of her own family who was presented as a "doctor" despite holding no medical registration.

The arithmetic of the sanction: two years + four years

The AIU decision stacks two separate violations. Two years for the presence of a prohibited substance. Four years for tampering with the investigation. Six years in total, counted from 10 September — the date she was provisionally suspended. The AIU announced the outcome on Thursday.

That arithmetic is revealing in itself. The 2 + 4 combination is standard under the Code's sanction structure — but it also means the panel rejected the "no significant fault" mitigation that would ordinarily reduce a presence sanction. The forged prescription closed that door.

A technical error about the substance

One technical point needs clearing up, because it changes how the whole case reads. Media reports described methylprednisolone as a "prohibited steroid." That is not accurate. It is a glucocorticoid, which sits in class S9 of the WADA Prohibited List — not in S1, the anabolic steroids.

The distinction matters. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A knee injection administered out-of-competition is entirely legal. It becomes a violation only if residues are present in an in-competition sample.

So the entire case turned not on "steroid use" but on two things: the route of administration, and its timing relative to the competition. In road racing, the testing window opens at 23:59 the day before the race — which means an injection given days earlier can still be caught.

That is exactly where Aga's defence could have worked. Intra-articular or peri-articular methylprednisolone for a knee injury is standard sports-medicine practice in distance runners; the explanation was entirely credible. Real medical records would have carried that defence. Instead of producing records, she manufactured one — and that is what flipped the case.

The chain behind the forged prescription

The AIU investigation surfaced three independent verification failures. First, the clinic named on the prescription did not exist. Second, the person who presented himself as a doctor had no medical registration; he was a family member. Third, that person claimed to have used "an old prescription pad from a former workplace" — and the clinic explicitly disowned the claim.

This is not a filing error. It is the signature of an athlete operating without a credentialed team physician. An athlete with a documented injury history would either hold or apply for a Therapeutic Use Exemption, or observe WADA's route-specific washout period. Neither happened here — and that is the strongest signal that the problem lies not with one athlete but with the informal medical network around her.

The career ledger

Aga entered global consciousness in 2026, when she won the Tokyo Marathon. Beyond that, she has three second-place finishes at World Marathon Majors races. That is the record of a genuinely elite marathoner.

The violation is anchored to the March race, which post-dates 2026. Absent evidence of earlier use, the 2026 achievement is not automatically annulled. It is also worth noting that the AIU decision does not spell out the scope of disqualification — although standard practice voids the result and prize money from the competition where the sample was collected.

But the ban length is the real punishment. Six years from age 32 means she returns at roughly 38. Given the depth of Ethiopian women's marathon running, a 38-year-old with a doping record is effectively unselectable. On paper it is a six-year ban; in practice it is the end of a career.

What actually caused it

Read the case in reverse and the root cause was not the drug — it was the knee injury. Chronic knee pathology is a well-known load-bearing failure mode in marathoners, generated by high-volume training. Injured runners face pressure to keep racing, because appearance-fee income depends on it. Glucocorticoids are the cheapest, most available tool against that pressure. And the surrounding medical network is informal.

Seen that way, the forged prescription was not a sudden decision but the product of a system in which no formal route to treatment existed. Whether the agent or management was investigated is unknown — the AIU statement names only the family member.

The competitive impact: nil

Sportingly, this decision will have no measurable effect on the Ethiopian or global marathon landscape. Aga holds no global championship medals; her three Major second places are commercial-tier results. In Ethiopian women's marathon running, even a 2:18 performer is not automatically selectable — the depth is such that one athlete's removal is invisible at national-team level.

What does change is the governance picture. A pattern is emerging in AIU road-racing cases: an initial substance violation, then a fabricated or altered explanation to cover it. The enforcement frontier has shifted from detection to document verification. Aga's case is not an outlier — it is a clean example of the category.

China's label-race circuit

The race where the sample was collected was a half marathon in China — presumably a World Athletics Label race, with an international elite field and both out-of-competition and in-competition testing. That circuit has long been a lucrative, low-risk income tier for East African marathoners between Majors. It is now also the AIU's highest-yield testing ground — the appearance-fee economy and the testing economy are colliding in the same races.

What could have been

Three scenarios frame this case. The worst — the one that materialised: six years, loss of the March result and its prize money, and the possibility of national-level action over the document forgery.

The middle scenario — what a competent defence could have achieved: with genuine medical records and a clear explanation of route and timing, the presence charge could have been argued toward the no-fault end, and no tampering charge would have arisen at all.

The best case: a TUE-consistent treatment plan and correct washout timing — and no case whatsoever.

The lesson

The sharpest lesson of this affair is that the drug did not destroy Aga. A six-year ban for a glucocorticoid is a striking outcome in itself — this is a substance with no proven endurance benefit. The decision will be cited both as evidence of AIU rigour and as evidence of disproportionate enforcement against African road runners.

But from the athlete's own vantage point the matter is simple: she erased the one defence that could actually have worked. Two years instead of six — that gap is the price of the single sheet of paper she had forged.